drugset / Trial / NCT07036185
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.
Timeline
- Start
- 2025-06-24
- Primary completion
- 2026-12-31
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KJ015 | Unknown | — | Subcutaneous |